{"name": "Molecular Partners",
 "permalink": "molecular-partners",
 "crunchbase_url": "http://www.crunchbase.com/company/molecular-partners",
 "homepage_url": "http://www.molecularpartners.com",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 2004,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@molecularpartners.com",
 "phone_number": "+41 44 755 77 00 ",
 "description": "",
 "created_at": "Fri Dec 18 09:24:07 UTC 2009",
 "updated_at": "Thu May 05 02:17:25 UTC 2011",
 "overview": "\u003Cp\u003EMolecular Partners AG, a biotechnology company, engages in the discovery and development of Designed Ankyrin Repeat Proteins (DARPins) based on the designed repeat protein technology. The company focuses on therapeutic, diagnostic, and biotechnological applications of DARPins. DARPins are binding proteins that show activity against various disease targets, including cell surface receptors, cytokines, proteases, kinases, and viral coat proteins. The company was incorporated in 2004 and is based in Zurich, Switzerland.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       49],
      "assets/images/resized/0007/0288/70288v1-max-150x150.jpg"],
     [[185,
       61],
      "assets/images/resized/0007/0288/70288v1-max-250x250.jpg"],
     [[185,
       61],
      "assets/images/resized/0007/0288/70288v1-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "CEO",
    "person":
     {"first_name": "Christian",
      "last_name": "Zahnd",
      "permalink": "christian-zahnd",
      "image": null}},
   {"is_past": false,
    "title": "CFO",
    "person":
     {"first_name": "Andreas",
      "last_name": "Emmenegger",
      "permalink": "andreas-emmenegger",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$59.8M",
 "funding_rounds":
  [{"round_code": "b",
    "source_url": "https://www.fis.dowjones.com/article.aspx?ProductIDFromApplication=29\u0026aid=DJFVLS0020091216e5cg00001\u0026r=Rss\u0026s=DJFVLS",
    "source_description": "Swiss Protein Therapy Co. Molecular Partners Pulls In $44M Series B  ",
    "raised_amount": 44200000.0,
    "raised_currency_code": "USD",
    "funded_year": 2009,
    "funded_month": 12,
    "funded_day": 16,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Essex Woodlands Health Ventures",
         "permalink": "essex-woodlands-health-ventures",
         "image":
          {"available_sizes":
            [[[150,
               83],
              "assets/images/resized/0005/2525/52525v3-max-150x150.jpg"],
             [[250,
               139],
              "assets/images/resized/0005/2525/52525v3-max-250x250.jpg"],
             [[268,
               150],
              "assets/images/resized/0005/2525/52525v3-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Index Ventures",
         "permalink": "index-ventures",
         "image":
          {"available_sizes":
            [[[150,
               68],
              "assets/images/resized/0005/1550/51550v1-max-150x150.png"],
             [[156,
               71],
              "assets/images/resized/0005/1550/51550v1-max-250x250.png"],
             [[156,
               71],
              "assets/images/resized/0005/1550/51550v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Johnson \u0026 Johnson Development",
         "permalink": "johnson-johnson-development",
         "image":
          {"available_sizes":
            [[[150,
               61],
              "assets/images/resized/0003/2806/32806v1-max-150x150.png"],
             [[206,
               85],
              "assets/images/resized/0003/2806/32806v1-max-250x250.png"],
             [[206,
               85],
              "assets/images/resized/0003/2806/32806v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "BB Biotech Ventures",
         "permalink": "bb-biotech-ventures",
         "image":
          {"available_sizes":
            [[[150,
               21],
              "assets/images/resized/0004/9243/49243v2-max-150x150.png"],
             [[250,
               36],
              "assets/images/resized/0004/9243/49243v2-max-250x250.png"],
             [[280,
               41],
              "assets/images/resized/0004/9243/49243v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Endeavour Capital",
         "permalink": "endeavour-capital",
         "image":
          {"available_sizes":
            [[[150,
               150],
              "assets/images/resized/0004/6941/46941v1-max-150x150.jpg"],
             [[158,
               158],
              "assets/images/resized/0004/6941/46941v1-max-250x250.jpg"],
             [[158,
               158],
              "assets/images/resized/0004/6941/46941v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "a",
    "source_url": "http://www.molecularpartners.com/cnt_press.php?pres=14",
    "source_description": "MOLECULAR PARTNERS SECURES $15.56 million IN SERIES A FINANCING",
    "raised_amount": 15560000.0,
    "raised_currency_code": "USD",
    "funded_year": 2007,
    "funded_month": 8,
    "funded_day": 14,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Index Ventures",
         "permalink": "index-ventures",
         "image":
          {"available_sizes":
            [[[150,
               68],
              "assets/images/resized/0005/1550/51550v1-max-150x150.png"],
             [[156,
               71],
              "assets/images/resized/0005/1550/51550v1-max-250x250.png"],
             [[156,
               71],
              "assets/images/resized/0005/1550/51550v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "BB Biotech Ventures",
         "permalink": "bb-biotech-ventures",
         "image":
          {"available_sizes":
            [[[150,
               21],
              "assets/images/resized/0004/9243/49243v2-max-150x150.png"],
             [[250,
               36],
              "assets/images/resized/0004/9243/49243v2-max-250x250.png"],
             [[280,
               41],
              "assets/images/resized/0004/9243/49243v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Johnson \u0026 Johnson Development Corporation",
         "permalink": "johnson-johnson-development-corporation",
         "image":
          {"available_sizes":
            [[[150,
               57],
              "assets/images/resized/0005/8402/58402v1-max-150x150.png"],
             [[225,
               86],
              "assets/images/resized/0005/8402/58402v1-max-250x250.png"],
             [[225,
               86],
              "assets/images/resized/0005/8402/58402v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Endeavour Capital",
         "permalink": "endeavour-capital",
         "image":
          {"available_sizes":
            [[[150,
               150],
              "assets/images/resized/0004/6941/46941v1-max-150x150.jpg"],
             [[158,
               158],
              "assets/images/resized/0004/6941/46941v1-max-250x250.jpg"],
             [[158,
               158],
              "assets/images/resized/0004/6941/46941v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "Wagistrasse 14",
    "address2": "Z\u00c3\u00bcrich-Schlieren",
    "zip_code": "8952",
    "city": "Z\u00c3\u00bcrich",
    "state_code": null,
    "country_code": "CHE",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "Allergan snags rights to retinal disease drug in $420M pact",
    "stoned_year": 2011,
    "stoned_month": 5,
    "stoned_day": 4,
    "source_url": "http://www.fiercebiotech.com/story/allergan-snags-rights-retinal-disease-drug-420m-pact/2011-05-04?utm_medium=rss\u0026utm_source=rss",
    "source_text": "",
    "source_description": "Allergan snags rights to retinal disease drug in $420M pact",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Molecular Partners",
      "permalink": "molecular-partners"}}],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        82],
       "assets/images/resized/0007/0287/70287v1-max-150x150.jpg"],
      [[250,
        137],
       "assets/images/resized/0007/0287/70287v1-max-250x250.jpg"],
      [[450,
        246],
       "assets/images/resized/0007/0287/70287v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}